Insights from pre-clinical studies for new combination treatment regimens with the Bcr-Abl kinase inhibitor imatinib mesylate (Gleevec/Glivec) in chronic myelogenous leukemia: A translational perspective

P. La Rosée, M. E. O'Dwyer, B. J. Druker

Research output: Contribution to journalArticlepeer-review

84 Scopus citations

Fingerprint

Dive into the research topics of 'Insights from pre-clinical studies for new combination treatment regimens with the Bcr-Abl kinase inhibitor imatinib mesylate (Gleevec/Glivec) in chronic myelogenous leukemia: A translational perspective'. Together they form a unique fingerprint.

Medicine & Life Sciences